In vivo safety prediction of recombinant collagen using in vitro simulated degradation analysis, chronic toxicity and immunological evaluation
Regenerative Biomaterials · 22.01.2026 · 13
DOI: 10.1093/rb/rbaf128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Regenerative Biomaterials, online erschienen am 09.12.2025. Verfasst von Can Huang und 14 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu High-level Innovative and Entrepreneurial Talents, Beijing Natural Science Foundation, China NMPA Research on Performance and Safety Evaluation of Innovative Biomaterial Medical Devices.
Abstract (Originalsprache)
Protein-based biomaterials, particularly collagen-derived materials, have been widely applied in medical devices and regenerative medicine due to their excellent biocompatibility and tissue repair-promoting functions. However, the degradation of these materials in vivo may trigger immune responses and other physiological reactions, especially through interactions between degradation products and the immune system. To better evaluate their safety and efficacy, particularly regarding the potential immunotoxicological risks posed by degradation products, this study proposes a comprehensive evaluation framework combining degradation product simulation, immunotoxicological assessment and chronic toxicity testing, aiming to more fully identify potential risks during the degradation process. This study first simulated the degradation process in vitro, analyzing the compatibility of the resulting degradation products with human proteins to reveal potential molecular interaction risks. Based on this, a systematic immunotoxicological evaluation was conducted from multiple dimensions, including complement activation, humoral immunity, cellular immunity and inflammatory responses, to thoroughly assess the immunological safety of the material. Furthermore, chronic toxicity experiments confirmed the long-term biosafety and stability of the material. The results demonstrate that the established comprehensive evaluation framework provides new methodological support and reference for the in vivo long-term biological risk assessment. Using this framework, recombinant type III collagen was found to exhibit favorable biosafety and immunological compatibility at the molecular, immune and systemic toxicity levels.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China.
- College of Biomedical Engineering, Sichuan University, Chengdu 610064, China.
- Jiangsu Trautec Medical Technology Co., Ltd, Changzhou 213200, China.
- Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.
- Sichuan Testing Centre for Biomaterials and Medical Devices, Chengdu 610064, China.
ORCID-Profile: Tun Yuan
Förderung
- Jiangsu High-level Innovative and Entrepreneurial Talents
- Beijing Natural Science Foundation
- China NMPA Research on Performance and Safety Evaluation of Innovative Biomaterial Medical Devices
Zitieren
APA
Huang, C., Li, J., Aou, X., He, H., Chu, Y., Gao, J., Le, H., Wang, X., Sun, H., Wang, H., Zhu, Z., Fan, Y., Zhang, G., Fan, X., & Yuan, T. (2026). In vivo safety prediction of recombinant collagen using in vitro simulated degradation analysis, chronic toxicity and immunological evaluation. Regenerative Biomaterials, 13. https://doi.org/10.1093/rb/rbaf128
Vancouver
Huang C, Li J, Aou X, He H, Chu Y, Gao J, et al. In vivo safety prediction of recombinant collagen using in vitro simulated degradation analysis, chronic toxicity and immunological evaluation. Regenerative Biomaterials. 2026;13. doi:10.1093/rb/rbaf128
BibTeX
@article{Huang2026,
author = {Huang, Can and Li, Jie and Aou, Xueyimu and He, Hongwei and Chu, Yun and Gao, Jianping and Le, Hao and Wang, Xinhui and Sun, Huilin and Wang, Huimin and Zhu, Ziqing and Fan, Yujiang and Zhang, Guifeng and Fan, Xiaoju and Yuan, Tun},
title = {In vivo safety prediction of recombinant collagen using in vitro simulated degradation analysis, chronic toxicity and immunological evaluation},
journal = {Regenerative Biomaterials},
year = {2026},
volume = {13},
doi = {10.1093/rb/rbaf128}
}
EUVIMED